Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its Chief Executive Officer Ivor Elrifi has bought 163,400 shares of the biotechnology company’s common stock in the open market, increasing his total purchased holdings to 357,848 shares.
The Nasdaq-listed company is developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody.